Cleerly
Cleerly is a digital healthcare company whose AI-powered platform analyzes CT scans for quantitative coronary artery disease plaque assessment.
Secondary Market Price
How Cleerly Measures Up
To help you manage your Cleerly equity, Prospect has run the company through our machine learning model.
Prospect Rating
This rating reflects our belief in this company's potential to grow to that many times its current value in 4 years. For an employee with stock, this rating suggests a potential return on equity, but it also comes with some risk.
Exit Risk
--
Our rating is a reflection of the likelihood of this company achieving a liquidity event for its employees based on the quality of investors, funding stage, founders, and more.
Funding Stage
Series C
A company’s funding stage reflects how established it is, how quickly it is scaling, and the average impact an employee may have when joining.
Secondary Market Price Chart
Create a free account to unlock real-time secondary market prices and future projections of Cleerly's value.
Sign up to Unlock the Latest DataData will be available soon.
Sign up to receive notifications when it is available.
Prospect Projected Future Cleerly Prices
Prospect’s machine learning model has been trained on the same data top-tier investors use to project the likely range of outcomes for Cleerly's equity. Create a free account to view 10th-90th percentile projections over 2, 4, and 6 years.
Powerful tools to earn more from your equity
Company Description
Cleerly is a digital healthcare company that has developed an AI-powered platform for the diagnosis of heart disease. The company's solutions provide a comprehensive analysis of coronary artery disease by evaluating advanced non-invasive CT imaging, which helps physicians with diagnosis, treatment plans, and clinical decisions. Founded in 2017 by James K. Min, Cleerly is headquartered in Denver, Colorado, and its approach is based on science from nearly 20 years of multi-center clinical trials.
Recent developments indicate a period of significant adoption for Cleerly's technology. Major insurance providers, including Aetna, UnitedHealthcare, Cigna, and Humana, now provide coverage for the company's AI-enabled plaque analysis. Additionally, this analysis can now be billed using the Category I CPT® Code 75577, a change that moves the technology from an experimental classification to a recognized tool. Cleerly was involved in championing the development of this code with the American Medical Association for over five years. The company is focused on expanding access to its technology and is preparing for future regulatory changes, such as the Centers for Medicare & Medicaid Services 2026 Final Rule for AI-enabled medical imaging.
- Insight Partners
- Battery Ventures
- T. Rowe Price Associates, Inc.
- Fidelity Management and Research Company
- Sands Capital
- Piper Sandler’s Merchant Banking and Heartland Healthcare Capital funds
- Mirae Asset Capital
- Peter Thiel
- Breyer Capital
- Novartis
- Vensana Capital
- LRVHealth
- New Leaf Ventures
- Cigna Ventures
- DigiTx Partners
- Founder, CEO James K. Min
Peer Group Comparison
Vs Peer Group of >$4B Startups
Frequently Asked Questions
Joining Anduril as an employee is another way to acquire equity, typically through stock options included in compensation packages.
Is Cleerly worth joining?
Deciding whether to join any startup depends on your personal career goals and your belief in the company's mission and potential for success. A significant part of your compensation may be equity, so understanding its potential value is a crucial part of your decision.
What should I do with my Cleerly stock?
Managing private company stock involves complex decisions around exercising options, selling shares, and minimizing your tax burden. Platforms like Prospect provide tools and personalized strategies to help you make more informed choices about your equity.
Can you sell Cleerly stock?
It is often possible to sell shares in a private company like Cleerly through secondary markets or during a company-organized tender offer. Tools are available to help you navigate the process and determine which shares are most tax-optimal to sell.
How can I find the value of my Cleerly stock?
Valuing private stock can be difficult, as it isn't publicly traded and its price isn't readily available. You can use a platform like Prospect, which uses predictive models and secondary market data to help you forecast the potential future value of your shares.
What is Cleerly's equity worth?
The value of a private company's equity is typically determined by its most recent 409A valuation or the valuation set during its last funding round. For a personalized forecast of your holdings, equity management platforms can model potential future outcomes based on various market data.
What is Cleerly's stock ticker symbol?
As a privately held company, Cleerly does not have a stock ticker symbol. Ticker symbols are only assigned to companies when they list their shares for trading on a public stock exchange, such as the NYSE or NASDAQ.
Can I buy or sell Cleerly stock?
Selling private stock is often possible through secondary markets, and platforms like Prospect offer tools to help manage these sales. Buying shares, however, is typically more restricted and usually limited to accredited investors or participants in a formal funding round.
What is the criteria to buy or invest in Cleerly stock?
Investing directly in a private company is generally reserved for accredited investors who meet specific income or net worth requirements defined by regulators. Employees, on the other hand, can receive equity as part of their compensation without needing to meet these financial criteria.
